Healthy returns: Structure Therapeutics CEO on its obesity pill, combinations and future of GLP-1s

Structure Therapeutics CEO Ray Stevens talked about the biotech’s path forward and his expectations for the future of the ...

Structure Therapeutics CEO Says Compounding Threat Looms For Future Obesity Treatments

Structure CEO warns compounded weight-loss drugs could threaten new obesity treatments as the company prepares to bring its ...

A 10% Owner Of Structure Therapeutics Shed Shares

A company controlled by the Johnson family sold thousands of shares of this clinical-stage biopharmaceutical company, but ...

Structure expects pills to capture up to 50% of GLP-1 obesity market by 2030

Structure Therapeutics' CEO expects oral weight-loss pills to capture as much as half of the GLP-1 market by 2030, driven partly by pent-up demand from patients and doctors. Structure estimates a ...